DV
Dividend Vision

CGON — CG Oncology, Inc.

CG Oncology, Inc. (CGON)

Total return is 101.9% over the past 2.6 years, 38.0 points ahead of SPY at 63.9%. Its deepest 1-year drawdown was 27.4%.

CGON appears to be a single-stock equity security rather than a diversified ETF, tracking CG Oncology, Inc. with no reported dividend distribution rate or yield profile. The fund lacks standard ETF characteristics including distribution frequency, expense ratio data, and significant assets under management since its January 2024 inception. This security may appeal primarily to investors seeking direct exposure to oncology-focused equities rather than those pursuing dividend income strategies.

CGON key facts

Asset type
Stock
Asset class
Equity
Inception date
01/25/2024
Distribution frequency
None
Last close
$75.03
Market cap
$6,824,422,400
Average volume
596300.0
Beta
0.23
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.69